Stay updated on ACP-196 and Pembrolizumab in Pancreatic Cancer Clinical Trial
Sign up to get notified when there's something new on the ACP-196 and Pembrolizumab in Pancreatic Cancer Clinical Trial page.

Latest updates to the ACP-196 and Pembrolizumab in Pancreatic Cancer Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoChange DetectedAdded a government-status notice and a v3.2.0 revision; removed the v3.1.0 revision. The page now informs users about potential delays and where to check current operating status, and indicates the new version.SummaryDifference6%
- Check15 days agoChange Detected- Updated version from v3.0.2 to v3.1.0. - No other content changes detected.SummaryDifference0.1%
- Check22 days agoNo Change Detected
- Check29 days agoChange DetectedPage revision updated from v3.0.1 to v3.0.2; the 'Back to Top' link was removed.SummaryDifference0.3%
- Check37 days agoChange DetectedThe web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content. There are no significant changes in core content or other important factors.SummaryDifference0.3%
- Check44 days agoChange DetectedThe web page has undergone significant changes, including the addition of a facility name and location, as well as updated drug information for Acalabrutinib and Pembrolizumab. However, several key details, such as specific location terms and previous drug information, have been removed.SummaryDifference4%
- Check58 days agoChange DetectedThe web page has been updated from version v2.16.11 to v2.16.12.SummaryDifference0.1%
Stay in the know with updates to ACP-196 and Pembrolizumab in Pancreatic Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the ACP-196 and Pembrolizumab in Pancreatic Cancer Clinical Trial page.